AiCuris-Team mit dem Deutschen Zukunftspreis 2018 ausgezeichnet

              AiCuris-Team receives German Future Prize 2018


28. November 2018

Video ZDF:
Team 2
Schutz bei fehlendem
12. September 2018
Presentation Munich
Team 2
"Nominierungen zum
Deutschen Zukunftspreis 2018"
Video / Podcast
Team 2
erschließt neue Perspektiven
in der Transplantationsmedizin


 Welcome to AiCuris: The Powerhouse for Anti-Infectives

AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

Cooperation with Cyclenium


AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives

AiCuris and Cyclenium announced today the signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases.





Read more ...

AIC649 Positive Phase 1 Hepatitis B


AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B

  • Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups
  • The trial provides evidence that AIC649 stimulates the immune system of chronic hepatitis B patients
  • Further trials to study the potential of AIC649 to induce a functional cure in chronic hepatitis B virus (HBV)-infection is warranted 

 Read more ...

Job Opportunities

Join AiCuris and its quest for novel Anti-Infectives

We offer an exciting and challenging working enviroment in an innovative company with a world-class  R&D Portfolio. 






Read more ...